BRVE
Braveheart Bio, Inc.
Price Chart
Latest Quote
$21.77
-0.10 (-0.43%)
Current Price
| Previous Close | $21.87 |
| Open | $22.00 |
| Day High | $22.22 |
| Day Low | $21.38 |
| Volume | 29,851 |
Stock Information
| Shares Outstanding | 90.04M |
| Total Debt | $575K |
| Cash Equivalents | $122.83M |
| Net Income | $-98.45M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.96B |
| EPS (TTM) | $-6.08 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.88B |
| Income | $-98.45M |
| Book/sh | $-12.73 |
| Cash/sh | $1.36 |
| Employees | 49 |
Financial Ratios
| Quick Ratio | 13.56 |
| Current Ratio | 13.63 |
| Debt/Eq | 0.49 |
Returns & Margins
Ownership
| Insider Ownership | 58.16% |
| Institutional Ownership | 28.12% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -10.96 |
| P/B | -1.71 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $45.25 |
Technical Indicators
| SMA20 | $20.31 |
| SMA50 | $23.89 |
| RSI | 72.63 |
| ATR | 1.3264 |
| Shares Float | 12.72M |
| Short Ratio | 6.92 |
| Rel Volume | 0.42 |
Performance History
| Week | +7.65% |
| Month | +3.56% |
| YTD | -26.78% |
| 10 Years | -26.78% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $21.82 | 156,109 |
| 2026-10-26 | $21.87 | 101,200 |
| 2026-10-23 | $21.44 | 119,600 |
| 2026-10-22 | $21.48 | 156,500 |
| 2026-10-21 | $21.04 | 224,100 |
| 2026-10-20 | $20.27 | 323,900 |
| 2026-10-19 | $19.21 | 333,700 |
| 2026-10-16 | $18.71 | 414,900 |
| 2026-10-15 | $19.55 | 206,100 |
| 2026-10-14 | $19.34 | 462,800 |
| 2026-10-13 | $19.33 | 212,300 |
| 2026-10-12 | $20.36 | 155,100 |
| 2026-10-09 | $20.02 | 255,000 |
| 2026-10-08 | $19.09 | 389,200 |
| 2026-10-07 | $18.58 | 336,900 |
| 2026-10-06 | $19.79 | 590,300 |
| 2026-10-05 | $21.35 | 889,000 |
| 2026-10-02 | $21.27 | 462,800 |
| 2026-10-01 | $21.41 | 669,400 |
| 2026-09-30 | $20.20 | 967,500 |
| 2026-09-29 | $22.34 | 719,200 |
| 2026-09-28 | $21.07 | 389,300 |
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on BRVE.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Per Share | |
| Diluted EPS | $-5.32 |
| Basic EPS | $-5.32 |
| Other | |
| Diluted Average Shares | $12,411,309 |
| Basic Average Shares | $12,411,309 |
Fetched: 2026-10-27
Balance Sheet (Annual)
| Metric | 2025-12-31 |
|---|---|
| Other | |
| Ordinary Shares Number | $73,152,838 |
| Share Issued | $73,152,838 |
Fetched: 2026-10-27